Docetaxel: its role in current and future treatments for advanced gastric cancer.
about
Taxanes in the Treatment of Advanced Gastric CancermRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancerNeoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trialsNon-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Molecular targeting to treat gastric cancer.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivoInduction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis.Upregulation of leukotriene receptors in gastric cancer.Strategies for gastric cancer in the modern era.Non-curative gastric resection for patients with stage 4 gastric cancer--a single center experience and current review of literature.Second-line chemotherapy for advanced gastric cancer in Korea.Metastatic gastric cancer treatment: a little slow but worthy progress.Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Intraperitoneal delivery of a small interfering RNA targeting NEDD1 prolongs the survival of scirrhous gastric cancer model mice.The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis.Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery.Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis.The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience.The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios.Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer.Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis.A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
P2860
Q26747708-63B372FB-34D5-4F35-8E0F-5224777F1938Q28246258-DE171B4F-7E44-4EFA-A7A1-A41372F79323Q31150068-D6EEDD9A-416C-4DD4-BF39-A0B0706D72DDQ33594906-DE8E613C-5B3F-4317-97E6-833D77D5384EQ33889328-702BDA81-99A2-4ACD-8EFF-91A73962F482Q34326593-FE041561-5176-47D7-94CD-10531A826EBAQ34658209-9DC2D43A-7CAE-4990-8ABB-213D4BD76EB4Q35208277-2EA700F5-AAE8-4FED-AB31-AB281491D950Q35219054-A064F63B-04B6-48D6-8936-652B5CB8364EQ35927364-B744B2CA-DD31-4ED7-B1A0-5C00E271EA1BQ36058744-7F988516-5F80-4BA5-ADA5-B4C4DFB747B1Q36815168-23FA8449-0A99-41F1-A66B-10480D84B373Q37137400-8CDA5FCF-061F-41E5-AE38-F44662E4AA1DQ37821266-42725211-6D68-4F96-AA61-9A0EB112451BQ37981607-63A21CAD-A64E-49B8-9D4E-A66E9DFA4221Q37992841-9518539F-8DB2-451F-82EB-183157204842Q38075499-12E58AB5-56B7-4954-92ED-60B732980459Q38542060-B8C5FA9D-B0E1-464E-9207-12391B2FC8BCQ39252306-2F229A97-4678-428E-AC4B-5FA95C464ED2Q39403423-978AC9AF-1D51-4490-ABAA-8A1E651D5A70Q40208907-0B081E14-1770-439F-A2AC-BF56B179B217Q40617502-125FECBB-FC23-4865-8B36-AEF0B672B2B2Q43801555-B62B01DA-FA5E-4085-B9BD-290BD6366ABFQ43872716-D4A2D2D7-3107-43F7-B57C-8FA33947A65AQ43976543-54B09301-0F11-467E-8ED3-20A2D68E5519Q44898596-C0C9C744-6703-4FF0-8DD6-49A92A28E274Q46207048-B1C135BC-C91D-4E21-A60E-9506F6ED86AFQ49337286-20CB456F-E7A2-46F4-889B-867FCF911B6AQ50761729-2E3B7F98-BC00-4A55-AB36-BF7A6A8F85C9Q51028375-6EF598B3-4309-4840-99EE-0E3BD962A170Q54645262-7FB3CDFF-7772-456C-AA17-E7317ACC22B0
P2860
Docetaxel: its role in current and future treatments for advanced gastric cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@en
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@nl
type
label
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@en
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@nl
prefLabel
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@en
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@nl
P2860
P1433
P1476
Docetaxel: its role in current and future treatments for advanced gastric cancer.
@en
P2093
Masahiko Nishiyama
Satoru Wada
P2860
P2888
P304
P356
10.1007/S10120-009-0521-Z
P577
2009-11-05T00:00:00Z